Amiri et al. (2018) showed in vitro that FGF21 pretreatment decreased neuronal death of human neuronal SHSY5Y cells injured by Aβ1–42—directly linking to the possible benefits of FGF21 therapy in the setting of Alzheimer's disease. The gene discussed is FGF21; the disease is early-onset autosomal dominant Alzheimer disease.